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Aim: To evaluate the success of a patient-specific intensity modulated radiation therapy
(IMRT) quality assurance (QA) practice for prostate cancer patients across multiple institu-
tions  using a questionnaire survey.
Background: The IMRT QA practice involves different methods of dose distribution verifica-
tion  and analysis at different institutions.
Materials and Methods: Two full-arc volumetric modulated arc therapy (VMAT) plan and 7
fixed-gantry IMRT plan with DMLC were used for patient specific QA across 22 institutions.





institution recalculated the dose distribution with fixed monitor units and without any
modification. Single-point dose measurement with a cylindrical ionization chamber and
dose  distribution verification with a multi-detector or radiochromic film were performed,
according to the QA process at each institution.
Results: Twenty-two institutions performed the patient-specific IMRT QA verifications.With  a single-point dose measurement at the isocenter, the average difference between
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the calculated and measured doses was 0.5 ± 1.9%. For the comparison of dose distribu-
tions,  18 institutions used a two or three-dimensional array detector, while the others
used  Gafchromic film. In the  test with dose difference/distance-to-agreement criteria of
3%−3  mm and 2%−2 mm with a 30% dose threshold, the median gamma pass rates were
99.3% (range: 41.7%–100.0%) and 96.4% (range: 29.4%–100.0%), respectively.
Conclusion: This survey was an informative trial to understand the verification status of
patient-specific IMRT QA measurements for prostate cancer. In most institutions, the point
dose  measurement and dose distribution differences met the desired criteria.







































Table 1 – Questionnaire items.
What is treatment machine?
Which is multi leaf collimator type, the millennium 120MLC or
High definition 120 MLC?
What version of the treatment planning system?
Which is deliverable technique, IMRT or VMAT?
What is the electrometer?
What is the phantom?
What is dose distribution verification tool?
What is software to compare the dose distribution?
Which do you use for comparison of dose distribution, absorbed or
relative dose?
Please specify the correlation factors regarding point dose
measurement.
Please specify planned dose (mean and standard deviation) of
IMRT/VMAT plan imported in your treatment planning system.
Please specify methodology of dose distribution verification in
your institution.
Please specify verification results for last 10 patients in your
institution.
What are planned and measured doses at isocenter in point.  Background
ntensity modulated radiation therapy (IMRT) and volume
odulated arc therapy (VMAT) have been introduced at
any institutions for the treatment of various cancers.1–6
hese techniques can create and shape more  complicated
ose distributions than conventional radiation therapy, which
ncreases the complexity of treatment plans. Therefore, IMRT
uality assurance (QA) verification is an important process
mployed to check the accuracy of IMRT  plan dose calculations
nd detect clinically relevant errors in the radiation deliv-
ry, thereby ensuring the safety of patients and the fidelity
f treatment.7 However, the IMRT  QA practice involves dif-
erent methods of dose distribution verification and analysis
t different institutions, because the institutions employ dif-
erent measurement tools, IMRT  planning systems, delivery
ystems, and IMRT/VMAT plans. As this study focuses on the
onsistency of IMRT  QA measurement results, the planning
nd delivery systems used by each institution were limited
o a single manufacturer. Furthermore, the IMRT/VMAT plans
ere created by the host center’s experienced planner, using
he same computed tomography (CT) image,  structure set, and
ose constraints. The patient-specific IMRT  QA was performed
ith the same IMRT/VMAT plans being used across the insti-
utions.
.  Aim
he purpose of this study was therefore to evaluate the
chievements of a multiple-institution patient-specific IMRT
A practice for prostate cancer patients, with a questionnaire
urvey being used for this purpose.
.  Materials  and  methods
.1.  Survey
wenty-two institutions participated in this study, with all
f them also participating in a treatment planning semi-
ar organized by the Japan Professional Accreditation Boardor Radiotherapy Technologists (RTT) in 2017. All institutions
sed the Varian linac and treatment planning system (Eclipse:
arian Medical Systems, Inc., Palo Alto, CA, USA). Of the
2 institutions, 18 were already treating patients with IMRTdose measurement?
What are gamma pass rates at 3%−3  mm and 2%−2 mm with
30% threshold?
and/or VMAT, and 4 were ready to start such treatments at
that time.
A 15-question internet-based survey on treatment equip-
ment and patient-specific IMRT QA was designed to study the
current state of practice in the 22 institutions. A question-
naire was emailed with a unique link to the survey describing
the purpose of the project and emphasizing the confidential-
ity of the responses. The survey was split into two  sections:
treatment and measurement equipment, and patient-specific
IMRT QA practice. The treatment and measurement equip-
ment covered the treatment machine, MLC  type, treatment
planning system (TPS) version, electrometer, phantom, and
dose distribution verification device, while the patient-specific
IMRT QA practice included the methodology, correction fac-
tors, and the verification results for the last 10 patients, as
shown in Table 1. The treatment equipment and delivery tech-
niques used in each institution are listed in Table 2. Twelve
centers used VMAT,  10 centers used IMRT,  and no center used
both.3.2.  IMRT  and  VMAT  planning
To focus on the consistency of patient-specific IMRT  QA mea-
surements between institutions, IMRT and VMAT  plans were
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Fig. 1 – Dose distributions of (a) 7 fixed-gantry IMRT  and (b) 2 full arcs VMAT  plans created by the host center’s experienced
planner.
Table 2 – List of equipment and delivery techniques in
the 22 institutions.
Institution Machine MLC  type Modality TPS
version
1 Novalis Tx HD120 VMAT 10
2 Novalis Tx HD120 IMRT 13
3 Clinac iX Millennium120 VMAT 11
4 TrueBeam STx HD120 VMAT 13
5 Clinac iX Millennium120 IMRT 11
6 Clinac iX Millennium120 VMAT 11
7 Trilogy Millennium120 IMRT 13
8 Clinac iX Millennium120 IMRT 13
9 Clinac iX Millennium120 IMRT 11
10 Novalis Tx HD120 VMAT 11
11 Novalis Tx HD120 IMRT 10
12 Trilogy Millennium120 IMRT 13
13 TrueBeam Millennium120 VMAT 13
14 Clinac iX Millennium120 IMRT 8
15 TrueBeam STx HD120 VMAT 13
16 Clinac iX Millennium120 IMRT 13
17 TrueBeam Millennium120 VMAT 13
18 TrueBeam Millennium120 IMRT 13
19 TrueBeam Millennium120 VMAT 13
20 TrueBeam STx HD120 VMAT 13
21 Clinac 21EX Millennium120 IMRT 15
22 TrueBeam Millennium120 VMAT 13
Table 3 – Dose constraints for the IMRT  and VMAT plans.
Structure Dose metric Dosimetric goal
PTV D95% ≥75.6 Gy
D98% ≥74.1 Gy







agreement criterion was performed with a 30% threshold,generated by an experienced planner working in the host
institution. Each IMRT  and VMAT  plan for the different types
of MLC  (Millennium 120 and High-definition 120 MLCs) were
created with the same CT image  and structure set acquired
from a patient with prostate cancer. Beam settings were 7
fixed-gantry and 10 MV  photons in the IMRT  plan, and 2 full
arcs (181◦ to 179◦; clockwise and counterclockwise) and 10 MV
photons in the VMAT  plan. Optimization processes were per-
formed with the same dose constraints for both the IMRT  and
VMAT  plans, as shown in Table 3. The prescribed dose was
78 Gy in 39 fractions for the mean dose to the planning target
volume. Fig. 1 shows the dose distributions for the IMRT and
VMAT  plans. The plans including the CT images and structures
in the DICOM-RT format were distributed to the 22 institu-
tions.D2% ≤80.0 Gy
Femoral head D2% ≤50.0 Gy
3.3.  Patient-specific  IMRT  measurements  at  the
isocenter
The dose distributions were recalculated with fixed monitor
units and without any modification to create the verification
plan for the phantom at each institution, with each institu-
tion’s treatment planning system being used for this purpose.
Point dose measurement was performed with a 0.6 cm3 ion-
ization chamber, which was calibrated in terms of absolute
dose to water traceable to a secondary standard. The measure-
ment was performed with all fields irradiating the institution’s
water equivalent phantom using the planned gantry and col-
limator rotations. The measurement point was positioned at
the isocenter. The collecting volume of the ionization chamber
was contoured on the institution’s water equivalent phantom
CT image,  and the planned dose was defined as the average
dose in the volume. The measured dose was corrected by the
daily output factor, to reduce the effects of daily linac output
variations and differences between the phantom and liquid
water.
The measured dose distributions were compared with
the dose distributions calculated by the treatment planning
system, with the measuring system and methodology follow-
ing the usual practice at each institution. A global gamma
test including 3% dose differences and a 3-mm distance-to-as is commonly used to reduce over-sensitivity to low dose
points and measurement uncertainty.8 Additionally, a stricter





































ig. 2 – The point dose differences between the measured an
%−2 mm criterion was used for comparisons between differ-
nt measurement tools.
.  Results
welve institutions used an I’mRT phantom (IBA Dosimetry,
ouvain-La-Neuve, Belgium), six institutions used an RT-3000-
EW phantom (R-TEC.INC, Nagano, Japan), two institutions
sed an ArcCHECK phantom (Sun Nuclear Corporation, Mel-
ourne, FL, USA), and two institutions used an RW3 phantom
PTW Freiburg, Freiburg, Germany). With the point dose mea-
urements, the mean percentage dose difference between the
easured and planned doses was 0.49 ± 1.86% (mean ± one
tandard deviation [1SD]). Fig. 2 shows the spread of the point
ose differences over all institutions. Larger dose differences
ver 2% were observed in six institutions. Four of these were
nstitutions that had not completed the commissioning pro-
ess to start using IMRT/VMAT in clinical practice (institution
umber 8, 11, 17, and 19 in Table 4). The other two showed
ositive or negative error trends, which were similar to the
erification results for the last 10 patients measured at their
nstitution as shown in Table 4 (institution number 12 and
0). The mean percentage dose difference was 0.24 ± 1.22%
n the 18 institutions that had started treatment with
MRT/VMAT.
For dose distribution measurement, six institutions used
 Delta4 (ScandiDos, Uppsala, Sweden), five institutions
sed an ArcCHECK, four institutions used Gafchromic EBT
lm (Ashland, Covington, KY, USA), five institutions used
apCHECK2 (Sun Nuclear Corporation), and two institutions
sed the Dolphin and COMPASS system (IBA Dosimetry,
ouvain-La-Neuve, Belgium). In the comparison of mea-
ured and planned dose distributions, the median gamma
ass rates were 96.4% (range: 29.4%–100.0%) and 99.3%range: 41.7%–100.0%) for the passing criteria of 2%−2 mm
nd 3%−3 mm,  respectively. Fig. 3 shows histograms of the
amma pass rate results at passing criteria of 3%−3 mm and
%−2 mm.anned doses for (a) IMRT  versus VMAT plans, (b) all plans.
5.  Discussion
To focus on the consistency of patient-specific IMRT  QA
results between institutions, this questionnaire survey was
performed only for Varian machines and Eclipse users, and the
same IMRT/VMAT plans were prepared across all institutions.
We found that the results of point dose measurements and
dose distribution verifications were consistent across most
institutions in Japan, even though the institutions employed
different measurement tools. Some institutions were also
found to show outlying values.
The results reported in this study were obtained using only
an online survey. In contrast, in multi-institutional clinical
trials, a phantom is generally sent to the participating institu-
tions. The phantom generally contains some structures, and
the treatment plan is created by each institution for exter-
nal audit.9,10 Jornet et al. studied multi-center comparisons
of IMRT  dose planning and pretreatment verification. They
found that all centers fulfilled the dosimetric goals, but that
plan quality and delivery complexity were heterogenous and
uncorrelated, depending on the manufacturer and planner’s
methodology.11 Jurado-Bruggeman et al. also observed simi-
lar results in VMAT dose planning across multiple centers.12
McGarry et al. observed a stronger correlation between plan
complexity and gamma pass rate with Varian linear accel-
erators in a multi-institutional dosimetry audit of VMAT.13
Therefore, validation of the consistency of patient-specific
IMRT QA verification between institutions should be per-
formed using the same IMRT/VMAT plan. In this study, the
participating institutions were required to re-calculate the
plans to create a verification plan with their own phantom.
Some studies showed highly similar beam data with some
small variations in standard field size and treatments across
multiple linear accelerators from the same manufacturer.14,15
This disregards the variations caused by beam data between
different machines by the same manufacturer. Different veri-
fication tools may show different gamma pass rates,16 but our
results did not show a tendency to depend on the verifica-
tion tools, even though the criterion of 2%−2 mm was used to
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Table 4 – The point dose verification results for the last 10 patients measured at their institution and results in the
present study.
Institution Errors of point dose verification for the last 10 patients (%) Present study
(%)
1 2 3 4 5 6 7 8 9 10
1 −0.3 −0.2 −0.5 −0.3 −0.3 −0.2 0.2 −0.6 0.1 −0.5 −0.6
2 0.1 0.0 −0.1 0.0 0.6 0.4 0.2 0.8 0.0 0.5 0.5
3 −2.4 −0.7 0.5 −1.4 0.8 1.7 −2.1 −0.5 0.3 0.1 −1.5
4 −0.3 0.4 0.8 0.2 0.3 0.1 −0.3 −0.3 0.0 −0.5 0.3
5 0 0.1 −0.8 −0.9 −0.7 −0.7 −0.7 −0.7 −0.2 −0.6 1.2
6 −1.6 −0.5 −0.8 −0.9 −0.6 −0.6 −0.9 0.5 −0.5 −0.8 0.1
7 1.3 0.7 1.4 1.3 1.6 1.2 1.0 1.5 1.8 1.3 1.2
8 No data 2.2
9 0.3 −1.2 −0.7 −1.7 −1.1 −1.3 0.0 −0.3 −0.1 −1.1 −1.4
10 0.2 1.1 0.5 0.2 1.2 1.4 0.4 0.8 0.4 0.5 0.1
11 3.4 2.9 1.8 3.4 2.2 No data −3.7
12 0.9 0.2 −0.7 −0.7 −0.5 −1.4 −1.4 −1.8 −1.8 −0.4 −2.4
13 −0.7 −0.1 0.0 −0.5 −0.4 −0.2 −0.7 0.4 −0.7 0.0 −0.3
14 −0.2 0.4 0.3 −0.3 −0.3 0.0 0.1 −0.3 0.8 −0.3 0.9
15 Unanswered 0.1
16 0.9 No data 0.8
17 No data 4.3
18 0.2 0.2 0.2 0.2 0.2 −0.1 1.5 1.5 0.5 1.3 1.9
19 No data 3.8
20 2.2 1.3 1.5 0.9 0.9 1.9 2.7 1.6 0.2 3.3 2.6
21 0.3 1.2 −0.9 −0.4 0.3 0.1 −0.4 1.4 0.2 0.2 −0.3
22 Unanswered 1.1
passFig. 3 – Histograms of the gamma  pass rate at 
detect subtle and systematic errors. In addition, there was no
tendency related to different linacs or TPS versions in mea-
surement results in this study. Our results, therefore, reflect
the patient-specific IMRT QA accuracy across multiple institu-
tions in Japan.
Very small variations were observed in the point dose
measurements. The instructions and guidelines for patient-
specific IMRT  QA measurements might be maintained in
Japan, and a standardized process is performed in most
institutions. Similarly, the results of the dose distribution
verification were almost identical, although two institutions
showed a gamma pass rate of approximately 90% for the
3%−3 mm criterion; however, both institutions showed good
agreement with the other institutions in the point dose mea-
surement. Of these two institutions, one used ArcCHECK anding criteria of (a) 3%−3 mm and (b) 2%−2 mm.
the other used Gafchromic film for dose distribution verifica-
tion. Generally, ArcCHECK provides high reproducibility and
stability for planning verification.17 Errors related to prepara-
tion or the measurement process would affect the results. Film
dosimetry requires efficient correcting for film inhomogeneity
and inter-scan variability,18 but the correction of these effects
might have been insufficient. The lowest gamma pass rates
in dose distribution verification were observed at the institu-
tion which had not completed the commissioning process to
start using IMRT/VMAT in clinical practice. This questionnaire
survey can improve patient-specific IMRT QA quality of each
institution in the feedback information.This study has some limitations. The information of the
MLC data, such as the leaf end transmission and inter-

















































[18]. Marrazzo L, Zani M, Pallotta S, et al. GafChromic® EBT3 filmsreports of practical oncology and 
nstitutions participating in this study, and these data have
he greatest impact on dose calculation in IMRT  and VMAT.
nd the target spot size is also one of the factors to affect
ose distribution. Furthermore, measurement error caused
y mechanical errors, such as misalignment of wall-mounted
asers, cannot be detected from this survey. The gamma pass
ate is a very indirect measure which can affect the outcome
uch as the algorithm settings used in computing the dose dis-
ribution, the detector system, the precision used for phantom
ositioning, etc.
.  Conclusion
his survey was an informative trial to understand the status
f the verification of patient-specific IMRT  QA measurements
or prostate cancer. In most institutions, the point dose
easurement and the dose distribution differences met  the
esired criteria.
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